PMC:7402624 / 3689-4313
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T28 | 21-27 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 90 | 116-124 | Species | denotes | patients | Tax:9606 |
| 94 | 143-151 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 95 | 276-284 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 101 | 406-415 | Species | denotes | SARS-CoV2 | Tax:2697049 |
| 102 | 552-560 | Species | denotes | patients | Tax:9606 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T29 | 143-151 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T30 | 276-284 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T31 | 406-410 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T45 | 21-27 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
| T46 | 212-213 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T47 | 571-572 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T19 | 285-297 | http://purl.obolibrary.org/obo/GO_0009405 | denotes | pathogenesis |
| T20 | 386-402 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune responses |
| T21 | 445-460 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T28 | 0-98 | Sentence | denotes | Indeed, convalescent plasma containing neutralizing antibodies can improve clinical symptoms (30). |
| T29 | 99-298 | Sentence | denotes | However, not all patients that recover from COVID-19 have detectable neutralizing antibodies (6, 26), suggesting a complex relationship between humoral and cellular response in COVID-19 pathogenesis. |
| T30 | 299-491 | Sentence | denotes | Taken together, this previous work provokes questions about the potential diversity of immune responses to SARS-CoV2 and the relationship of this immune response diversity to clinical disease. |
| T31 | 492-619 | Sentence | denotes | However, many studies describe small cohorts or even single patients, limiting a comprehensive interrogation of this diversity. |